Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Hilgeroth

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Journal of Medicinal Chemistry|February 21, 2003
Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating propertiesKristin Brachwitz, Burkhardt Voigt, Laurent Meijer, et al.
Chemmedchem|December 9, 2010
Discovery of 4-benzylamino-substituted α-carbolines as a novel class of receptor tyrosine kinase inhibitorsMartin Krug, Kanin Wichapong, German Erlenkamp, et al.
Journal of Medicinal Chemistry|August 22, 2008
Novel insight in structure-activity relationship and bioanalysis of P-glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3,9-diazatetraasteranesClaudius Coburger, Jörg Wollmann, Christiane Baumert, et al.
Future Medicinal Chemistry|December 24, 2021
Discovery of a novel class of small-molecule antibacterial agents against <i>Staphylococcus aureus</i>David Kreutzer, Robin Gehrmann, Annámaria Kincses, et al.
Bioorganic & Medicinal Chemistry Letters|October 9, 2012
Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinasesVolkmar Tell, Max Holzer, Lydia Herrmann, et al.
Future Medicinal Chemistry|August 3, 2022
Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer's diseaseAnsgar Opitz, Lisa-Marie Seitz, Vladimir Krystof, et al.
Bioorganic & Medicinal Chemistry|July 6, 2010
Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulatorsClaudius Coburger, Jörg Wollmann, Martin Krug, et al.
Drug Design, Development and Therapy|January 23, 2019
Antistaphylococcal evaluation of indole-naphthalene hybrid analogsKerolos Ashraf, Kaveh Yasrebi, Emmanuel Tola Adeniyi, et al.
Bioorganic & Medicinal Chemistry|December 4, 2012
Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal propertiesChristiane Baumert, Marianne Günthel, Sören Krawczyk, et al.
Bioorganic & Medicinal Chemistry Letters|March 22, 2014
Discovery of 4-anilino α-carbolines as novel Brk inhibitorsKazem Ahmed Mahmoud, Martin Krug, Tom Wersig, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Journal of Medicinal Chemistry|February 21, 2003
Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating propertiesKristin Brachwitz, Burkhardt Voigt, Laurent Meijer, et al.
Chemmedchem|December 9, 2010
Discovery of 4-benzylamino-substituted α-carbolines as a novel class of receptor tyrosine kinase inhibitorsMartin Krug, Kanin Wichapong, German Erlenkamp, et al.
Journal of Medicinal Chemistry|August 22, 2008
Novel insight in structure-activity relationship and bioanalysis of P-glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3,9-diazatetraasteranesClaudius Coburger, Jörg Wollmann, Christiane Baumert, et al.
Future Medicinal Chemistry|December 24, 2021
Discovery of a novel class of small-molecule antibacterial agents against <i>Staphylococcus aureus</i>David Kreutzer, Robin Gehrmann, Annámaria Kincses, et al.
Bioorganic & Medicinal Chemistry Letters|October 9, 2012
Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinasesVolkmar Tell, Max Holzer, Lydia Herrmann, et al.
Future Medicinal Chemistry|August 3, 2022
Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer's diseaseAnsgar Opitz, Lisa-Marie Seitz, Vladimir Krystof, et al.
Bioorganic & Medicinal Chemistry|July 6, 2010
Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulatorsClaudius Coburger, Jörg Wollmann, Martin Krug, et al.
Drug Design, Development and Therapy|January 23, 2019
Antistaphylococcal evaluation of indole-naphthalene hybrid analogsKerolos Ashraf, Kaveh Yasrebi, Emmanuel Tola Adeniyi, et al.
Bioorganic & Medicinal Chemistry|December 4, 2012
Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal propertiesChristiane Baumert, Marianne Günthel, Sören Krawczyk, et al.
Bioorganic & Medicinal Chemistry Letters|March 22, 2014
Discovery of 4-anilino α-carbolines as novel Brk inhibitorsKazem Ahmed Mahmoud, Martin Krug, Tom Wersig, et al.
Pageof 7